ArticleClinical and translational radiation oncology2024
Systemic inflammatory markers and volume of enhancing tissue on post-contrast T1w MRI images in differentiating true tumor progression from pseudoprogression in high-grade glioma.
Article in Clinical and translational radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Systemic Inflammation and Risk of Thromboembolism, Mortality, and Treatment Response in Patients With Cancer Receiving Immune Checkpoint Inhibitors.European journal of clinical investigation · 2026Article
- Platelet-to-Albumin Ratio and Clinical Outcomes in IDH-Wildtype Grade 4 Diffuse Glioma.Journal of clinical medicine · 2026Article
- Peripheral hematological landscapes as biomarkers for detecting postoperative progression in glioblastoma multiforme: a multivariable risk scoring approach.Journal of neuro-oncology · 2026Article
- Organoids to Model Tumor Microenvironment in Progression of Pathogenesis and Treatment Resistance in Glioblastoma Multiforme.Brain sciences · 2026Review
- Article
- Transformer-Based Deep Learning Model for Predicting Recurrence in High-Grade Glioma.Cancer medicine · 2026Article
- Editorial: Intraoperative Visualization Techniques and Advanced Imaging in Brain Tumors.Cancers · 2026Article
- Development and characterization of a novel B7-H3 rabbit monoclonal antibody for glioma diagnosis.Frontiers in pharmacology · 2026Article
- CAR-T Cell Therapy in Glioblastoma: Overcoming Immunological Barriers and Advancing Clinical Translation.Cancer management and research · 2026Review
- Multimodal artificial intelligence in glioma management: integrating neuroimaging and hematologic biomarkers for precision oncology.Frontiers in oncology · 2026Review
- Calibrated and explainable multiparametric MRI radiomics for differentiating tumor positive disease from treatment-related changes in glioblastoma.Frontiers in oncology · 2026Article
- Acute radiation-induced brain injury in patients with glioma and the construction of a clinical prediction model: a cohort study.Translational cancer research · 2025Article
- The diagnostic value of advanced tracer kinetic models in evaluating high grade gliomas recurrence and treatment response using dynamic contrast-enhanced MRI.Frontiers in oncology · 2025Article
- Blood-Based Prognostic Prediction Model for Glioblastoma: Construction and Validation.Cancer management and research · 2025Article
- A prospective observational study of inflammatory mediators in cerebrospinal fluid after intraoperative radiotherapy of brain tumors.Therapeutic advances in medical oncology · 2025Article
- Predicting Glioma Recurrence Using 18F-FDG PET/CT, MRI, and Tumor Markers: A Combined Approach.International journal of general medicine · 2025Article
- Network Analysis of Multidimensional Symptoms and Inflammatory Biomarkers in Chinese Patients with Glioma.Journal of inflammation research · 2025Article
- Better performance of cerebral blood volume images synthesized from arterial spin labeling and standard MRI in separating glioblastoma recurrence from treatment response than arterial spin labeling.Frontiers in oncology · 2025Article
- The Predictive Value of ADC Values, Degree of Edema and the Systemic Immune-Inflammation Index for Early Postoperative Recurrence in High-Grade Gliomas.Journal of inflammation research · 2025Article
- Serum Response Factor Expression, Microvascular Density, and Postoperative Recurrence in Glioblastoma.OncoTargets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-grade glioma (HGG) patients post-radiotherapy often face challenges distinguishing true tumor progression (TTP) from pseudoprogression (PsP). This study evaluates the effectiveness of systemic inflammatory markers and volume of enhancing tissue on post-contrast T1 weighted (T1WCE) MRI images for this differentiation within the first six months after treatment. Material and Methods: We conducted a retrospective analysis on a cohort of HGG patients from 2015 to 2021, categorized per WHO 2016 and 2021 criteria. We analyzed treatment responses using modified RANO criteria and conducted volumetry on T1WCE and T2W/FLAIR images.Blood parameters assessed included neutrophil/lymphocyte ratio (NLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI). We employed Chi-square, Fisher's exact test, and Mann-Whitney Results: The cohort consisted of 39 patients, where 16 exhibited PsP and 23 showed TTP. Univariate analysis revealed significantly higher NLR and SII in the TTP group [NLR: 4.1 vs 7.3, p = 0.002; SII 546.5 vs 890.5p = 0.009]. T1WCE volume distinctly differentiated PsP from TTP [2.2 vs 11.7, p < 0.001]. In multivariate regression, significant predictors included NLR and T1WCE volume in the "NLR Model," and T1WCE volume and SII in the "SII Model." The study also found a significantly lower OS rate in TTP patients compared to those with PsP [HR 3.97, CI 1.59 to 9.93, p = 0.003]. Conclusion: Elevated both, SII and NLR, and increased T1WCE volume were effective in differentiating TTP from PsP in HGG patients post-radiotherapy. These results suggest the potential utility of incorporating these markers into clinical practice, though further research is necessary to confirm these findings in larger patient cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.